CPC A61K 35/28 (2013.01) [A61K 9/127 (2013.01); A61K 9/5068 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 35/35 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01); A61P 37/06 (2018.01); C12N 15/625 (2013.01); A61K 2035/122 (2013.01); A61K 2035/128 (2013.01); A61K 2300/00 (2013.01); C12N 5/0667 (2013.01); G01N 1/4077 (2013.01)] | 5 Claims |
1. A method of treating an immune-mediated inflammatory disease in a subject suffering from said disease, wherein the immune-mediated inflammatory disease is an inflammatory disease characterized by chronic inflammation and the immune-mediated inflammatory disease is selected from the group consisting of rheumatoid arthritis (RA), Inflammatory Bowel Disease (IBD), and Crohn's disease and wherein the method comprises administering to said subject a therapeutically effective amount of an isolated exosome population derived from MSCs, wherein the MSCs are adipose tissue-derived stem cells (ASCs) characterized in that:
the exosomes from said population comprise TSP-1.
|